This novel antibiotic adjuvant entity has been found effective against even the toughest carbapenemase resistant Metallobetalactamses
Venus Remedies has received patent from the US Patent Office for a breakthrough antibiotic product. The new drug product CSE1034 which is an antibiotic adjuvant entity (AAE), has been found to be effective against a wide range of drug resistant infections including the `superbugs’ like carbapenemase resistant Metallobetalactamses (MBL) strains. Venus Remedies is planning to launch this drug in India under the brand name ELORES and is planning to have a pre IND meeting with US FDA for fast track approval of this product.
“The US patent of CSE 1034 for Venus Remedies is a landmark development for initiating the process of commercialisation of this novel drug, designed specifically to target growing bacterial resistance mechanisms,” said Dr Mufti Suhail Sayeed, Vice President-Venus Medical Research Centre (VMRC), Venus Remedies.
“This unique antibiotics adjuvant entity creates a synergistic effect due to its activity on AMRINGER (Acquired Multiple Resistance in Gram Negative Enterococci and Rods) which stops development and spread of bacterial resistance. Experience with clinical studies on >1000 patients have indicated approximately 20-30 per cent reduction in cost of therapy compared to conventional therapies being used,” Dr Manu Chaudhary, Joint Managing Director-VMRC, Venus Remedies , said.
Studies conducted in hospitals across India have shown that the novel antibiotic adjuvant entity is suitable for the treatment of a range of infections affecting lower respiratory tract, urinary tract, skin and skin structure, bone and joint and conditions like meningitis, septicaemia, acute otitis media. The drug has been found safe while effectively dealing with hospital acquired (nosocomial) infections involving metallobetalactamase and other resistant strains such as E coli, K pneumoniae, P aeruginosa and A baumanni, with reduced drug induced toxicity resulting in lesser adverse effects.
Dr Arvinder Singh, Neuro-Anaesthesist and Neuro-Critical Care Specialist, Max Superspeciality Hopital, New Delhi said, “Anti-microbial resistance is increasing day-by-day and patient coming from different hospital settings have multi-drug resistance pathogen. Pathogen resistance is increasing against the highest order of antibiotics. It is about whole world but an Indian company getting patent in US for an innovation is a proud moment. Indian company taking a lead against Antimicrobial resistance is good for our country as we can get cheaper novel drugs.”
EP News Bureau – Mumbai